This protocol covers initial systemic management of metastatic colon adenocarcinoma in a molecularly defined subgroup: proficient mismatch repair (pMMR) / microsatellite stable (MSS) tumours with concurrent KRAS wild-type, NRAS wild-type, and BRAF V600E mutation status.
Patient population
Metastatic colon adenocarcinoma characterised by the following biomarker profile:
pMMR / MSS
KRAS wild-type
NRAS wild-type
BRAF V600E mutation
Treatment approach (partial overview)
Preferred first-line regimens in this setting combine a chemotherapy backbone with encorafenib and an EGFR inhibitor — with additional options forming part of the complete structured algorithm.
Full regimen details, all recommended and alternative options, and sequencing guidance are available in the complete protocol →